A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer

PURPOSE: The clinical success of arsenic trioxide (As(2)O(3)) in hematological malignancies has not been replicated in solid tumors due to poor pharmacokinetics and dose-limiting toxicity. We have developed a novel nanoparticulate formulation of As(2)O(3) encapsulated in liposomal vesicles or “nanob...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ahn, Richard W., Chen, Feng, Chen, Haimei, Stern, Stephan T., Clogston, Jeffrey D., Patri, Anil K., Raja, Meera R., Swindell, Elden P., Parimi, Vamsi, Cryns, Vincent L., O’Halloran, Thomas V.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2010
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2943376/
https://ncbi.nlm.nih.gov/pubmed/20519360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0068
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg